CELU vs. XBI
CELU (Celularity Inc.) is a stock, while XBI (SPDR S&P Biotech ETF) is Health & Biotech Equities fund tracking the S&P Biotechnology Select Industry Index. Over the past 5 years, CELU returned -61.44%/yr vs 3.97%/yr for XBI. At a 0.18 correlation, their price movements are largely independent.
Performance
CELU vs. XBI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CELU achieves a -27.03% return, which is significantly lower than XBI's 26.84% return.
CELU
- 1D
- 3.85%
- 1M
- 7.67%
- 6M
- -38.64%
- YTD
- -27.03%
- 1Y
- -74.29%
- 3Y*
- -47.60%
- 5Y*
- -61.44%
- 10Y*
- —
- ALL TIME*
- -49.84%
XBI
- 1D
- 2.36%
- 1M
- 9.90%
- 6M
- 23.44%
- YTD
- 26.84%
- 1Y
- 80.75%
- 3Y*
- 22.31%
- 5Y*
- 3.97%
- 10Y*
- 10.21%
- ALL TIME*
- 11.86%
CELU vs. XBI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
CELU Celularity Inc. | -27.03% | -46.63% | -15.93% | -80.82% | -74.80% | -53.45% | 10.55% | 1.53% |
XBI SPDR S&P Biotech ETF | 26.84% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 48.33% | 14.14% |
Correlation
The correlation between CELU and XBI is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.16 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Aug 8, 2019 | 0.18 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CELU vs. XBI — Risk / Return Rank
CELU
XBI
CELU vs. XBI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Celularity Inc. (CELU) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CELU | XBI | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.82 | ||
| Sortino ratioReturn per unit of downside risk | -5.18 | ||
| Omega ratioGain probability vs. loss probability | 0.84 | 1.47 | -0.63 |
| Calmar ratioReturn relative to maximum drawdown | -0.87 | 8.35 | -9.22 |
| Martin ratioReturn relative to average drawdown | -1.17 | 23.64 | -24.81 |
Loading charts...
Drawdowns
CELU vs. XBI - Drawdown Comparison
The maximum CELU drawdown since its inception was -99.54%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for CELU and XBI.
Loading charts...
Drawdown Indicators
| CELU | XBI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.54% | -63.89% | -35.65% |
Max Drawdown (1Y)Largest decline over 1 year | -85.59% | -9.72% | -75.87% |
Max Drawdown (3Y)Largest decline over 3 years | -91.41% | -32.99% | -58.42% |
Max Drawdown (5Y)Largest decline over 5 years | -99.54% | -54.00% | -45.54% |
Max Drawdown (10Y)Largest decline over 10 years | — | -63.89% | — |
Current DrawdownCurrent decline from peak | -99.37% | -10.61% | -88.76% |
Average DrawdownAverage peak-to-trough decline | -63.55% | -20.89% | -42.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 63.49% | 3.43% | +60.06% |
Volatility
CELU vs. XBI - Volatility Comparison
Celularity Inc. (CELU) has a higher volatility of 31.18% compared to SPDR S&P Biotech ETF (XBI) at 8.72%. This indicates that CELU's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CELU | XBI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 31.18% | 8.72% | +22.46% |
Volatility (6M)Calculated over the trailing 6-month period | 59.90% | 21.57% | +38.33% |
Volatility (1Y)Calculated over the trailing 1-year period | 95.34% | 26.69% | +68.65% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 121.95% | 32.35% | +89.60% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 105.19% | 31.94% | +73.25% |
Dividends
CELU vs. XBI - Dividend Comparison
CELU has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.37%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CELU Celularity Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.37% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Frequently Asked Questions
CELU and XBI have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CELU has higher volatility (31.18%) compared to XBI (8.72%). In terms of maximum drawdown, CELU dropped -99.54% vs XBI's -63.89%.
XBI currently has the higher Sharpe Ratio (3.04 vs -0.78), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CELU and XBI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer